ERBB2 and breast cancer: Using expression data of gene, miRNA, and protein from 150 breast cancer samples available at TCGA (Table 2),24 DIABLO was showcased to identify multi-omics signatures (putative biomarkers) that could distinguish the breast cancer subtypes, namely, Basal, HER2, and Luminal A.51 Thus, mixOmics can address both disease subtyping and biomarker prediction.